CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
about
CCL21 and IFNγ recruit and activate tumor specific T cells in 3D scaffold model of breast cancer.Chemokines as Cancer Vaccine Adjuvants.The role of chemokines in breast cancer pathology and its possible use as therapeutic targetsDepletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunityHER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: Gene gun is superior to jet injector in inducing CTL responses and protective immunityPhase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinomaClinical applications of mouse models for breast cancer engaging HER2/neu.Chemokine-based immunotherapy: delivery systems and combination therapies.CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model.CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive CancersSuppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.Applications of chemokines as adjuvants for vaccine immunotherapy.Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization.
P2860
Q33726546-140966BC-0E7A-4F94-A236-5AF1AC99C87BQ33792344-B51B2B7C-41F9-4829-AB9F-C4BCE41A5D49Q34069862-5C8F520C-7446-457D-A546-F5E55F4AFDB6Q34984596-55CECE56-87A3-4D0F-85F5-B83FB9607A0CQ36476095-0DBA01C6-3D17-47AF-95AB-44E2B3900AE4Q37355213-FED5B94C-81C0-4CA0-824A-53F4263796C9Q37557653-081195C0-1562-402E-9D0B-FE7083340B26Q37607675-70E4260E-97E8-473A-907E-DB490A327C67Q38040509-239859AC-16E1-4DAC-8294-FD51F8336344Q38779935-5E1270E1-0C91-468F-A768-78F7013C01F6Q39253157-3871AC61-FA81-447D-BD77-F95F48944E13Q40517920-BAF7CD76-7C45-416A-869A-9EBCA17937ACQ40674386-D8DEC704-4A93-4D15-9267-722A93C4A13EQ43522873-5BE785F2-6C1A-4430-8C7A-8B50E6CAEEE1Q47288431-FCA4277C-3597-4320-AEBE-98F494B11AD4Q54252199-B42B1406-AFBC-456C-8D93-E71DA697B4AC
P2860
CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
@en
CCL21
@nl
type
label
CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
@en
CCL21
@nl
prefLabel
CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
@en
CCL21
@nl
P2093
P2860
P356
P1433
P1476
CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
@en
P2093
A Pezzutto
G Baldenhofer
J Westermann
M Pham-Duc
M S Sayed Ahmed
T Nguyen-Hoai
P2860
P2888
P356
10.1038/CGT.2011.69
P577
2011-10-14T00:00:00Z